Sign up for our daily Newsletter and stay up to date with all the latest news!

Subscribe I am already a subscriber

You are using software which is blocking our advertisements (adblocker).

As we provide the news for free, we are relying on revenues from our banners. So please disable your adblocker and reload the page to continue using this site.
Thanks!

Click here for a guide on disabling your adblocker.

Sign up for our daily Newsletter and stay up to date with all the latest news!

Subscribe I am already a subscriber

Clever Leaves granted Brazilian GMP certification for cannabis products

Clever Leaves has received the Brazilian GMP certification from ANVISA, the Brazilian Health Regulatory Agency, to manufacture cannabis products for Brazilian patients. 

Similar to the strict standards of the EU-GMP certification, ANVISA's Brazilian-GMP certification ensures that patients receive the highest quality of medicine by preventing cases of product contamination, variations in compound concentrations, mix-ups, incorrect labeling, and more. The certification is required for the manufacturing and commercialization of cannabis products in Brazil. Clever Leaves' Colombia facility being awarded Brazilian-GMP marks the company's fifth international official certification and further attests to the high-quality and premium standard practices that Clever Leaves upholds in its production. Clever Leaves is the first and only medicinal cannabis company globally that has GMP certifications from the EU, Colombia, and Brazil.

"The awarding of Brazilian-GMP certification signifies a major milestone for Clever Leaves by further highlighting our commitment to producing high-quality and safe cannabis products that are trusted internationally and meet the highest regulatory standards. The Brazilian market, in particular, has the potential to become the largest cannabis market in Latin America and one of the largest globally. We look forward to further developing our presence in Brazil through our partners, with whom we are already distributing finished cannabis products to medical patients in the country," said Andres Fajardo, CEO of Clever Leaves.  

Brazil currently has a population of over 210 million and has a regulatory framework for the use of medical cannabis products authorized under the RDC 327/2019. In addition to making Clever Leaves one of the few cannabis companies outside of Brazil to receive ANVISA's GMP certification, this certification, along with the EU-GMP, will allow Clever Leaves to expand operations into new and existing markets throughout the 5 continents that recognize international GMP standards and enable patient access to Clever Leaves' high-quality products. 

For more information:
Clever Leaves
info@cleverleaves.com    
www.cleverleaves.com  

Publication date: